Tags

Type your tag names separated by a space and hit enter

Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy.
Oncology (Williston Park). 1991 Aug; 5(8):55-60; discussion 60-2, 65.O

Abstract

Bone metastases and hypercalcemia are common in patients with advanced cancer and may present major problems for physicians treating these patients. The recent development of the bisphosphonates has improved therapy for these two conditions. These compounds, pyrophosphate analogs with a P-C-P backbone, which binds tightly to calcified bone matrix, include etidronate, clodronate, and pamidronate. All three are useful for the treatment of hypercalcemia, but pamidronate seems to be the most effective. Currently investigational in the United States, pamidronate is now in active clinical testing. The author discusses the administration, dosage and side effects, and results of current studies.

Authors+Show Affiliations

University Department of Clinical Oncology, Weston Park Hospital, Sheffield, England.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

1834153

Citation

Coleman, R E.. "Bisphosphonate Treatment of Bone Metastases and Hypercalcemia of Malignancy." Oncology (Williston Park, N.Y.), vol. 5, no. 8, 1991, pp. 55-60; discussion 60-2, 65.
Coleman RE. Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy. Oncology (Williston Park). 1991;5(8):55-60; discussion 60-2, 65.
Coleman, R. E. (1991). Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy. Oncology (Williston Park, N.Y.), 5(8), 55-60; discussion 60-2, 65.
Coleman RE. Bisphosphonate Treatment of Bone Metastases and Hypercalcemia of Malignancy. Oncology (Williston Park). 1991;5(8):55-60; discussion 60-2, 65. PubMed PMID: 1834153.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy. A1 - Coleman,R E, PY - 1991/8/1/pubmed PY - 1991/8/1/medline PY - 1991/8/1/entrez SP - 55-60; discussion 60-2, 65 JF - Oncology (Williston Park, N.Y.) JO - Oncology (Williston Park) VL - 5 IS - 8 N2 - Bone metastases and hypercalcemia are common in patients with advanced cancer and may present major problems for physicians treating these patients. The recent development of the bisphosphonates has improved therapy for these two conditions. These compounds, pyrophosphate analogs with a P-C-P backbone, which binds tightly to calcified bone matrix, include etidronate, clodronate, and pamidronate. All three are useful for the treatment of hypercalcemia, but pamidronate seems to be the most effective. Currently investigational in the United States, pamidronate is now in active clinical testing. The author discusses the administration, dosage and side effects, and results of current studies. SN - 0890-9091 UR - https://www.unboundmedicine.com/medline/citation/1834153/Bisphosphonate_treatment_of_bone_metastases_and_hypercalcemia_of_malignancy_ L2 - https://medlineplus.gov/bonecancer.html DB - PRIME DP - Unbound Medicine ER -